Abstract
In the 1980s monoclonal antibodies promised an era of “magic” bullet therapies that could specifically kill tumor cells while leaving healthy tissues intact. But the need to covalently couple the killing agent (toxin, radioisotopes, etc.) limited their clinical potential. Now, new bispecific antibodies (BsAbs, or bi-functional antibodies) have been developed. The prototypic BsAb consists of two different specific binding sites, with one directed to the target antigen on the surface of tumor cells, and the other to a trigger molecule.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
